期刊
FUTURE MEDICINAL CHEMISTRY
卷 12, 期 21, 页码 1911-1923出版社
Newlands Press Ltd
DOI: 10.4155/fmc-2020-0221
关键词
BI-2852; GTPase; KRAS; small molecule inhibitors
资金
- Austrian Forschungsforderungsgesellschaft (FFG) [854341, 861507, 867897, 874517]
Activating mutations in the three human RAS genes,KRAS,NRASandHRAS, are among the most common oncogenic drivers in human cancers. Covalent KRAS(G12C)inhibitors, which bind to the switch II pocket in the 'off state' of KRAS, represent the first direct KRAS drugs that entered human clinical trials. However, the remaining 85% of non-KRAS(G12C)-driven cancers remain undrugged as do NRAS and HRAS and no drugs targeting the 'on state' have been discovered so far. The switch I/II pocket is a second pocket for which the nanomolar inhibitor BI-2852 has been discovered. Here, we elucidate inhibitor binding modes in KRAS, NRAS and HRAS on and off and discuss future strategies to drug all RAS isoforms with this one pocket.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据